Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glumetinib in MET-altered NSCLC (Real-world Digital Follow-up Study)
ChiCTR2400080439Phase 4Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of glumetinib in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Time to treatment discontinuation. Started Feb 2024; status: recruiting.
02
Drugs
glumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400080439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080439.